ABSTRACT
INTRODUCTION
Cell function is the integrated outcome of numerous cellular processes. It is therefore difficult to categorize the physiological condition of a cell accurately without a host of information about these processes. In some simplistic considerations, growth is used as an all-encompassing physiological descriptor. Growth (and growth rate) can usually be supplemented by an array of extracellular vari- * To whom correspondence should be addressed.
ables in describing cell function and physiology, such as respiration rate, or rate of glucose consumption, or by derivative quantities such as the rates of glycolysis, TCA cycle activity, pentose phosphate pathway flux, etc. (Vallino and Stephanopoulos, 1993; Vangulik and Heijnen, 1995; Stephanopoulos, 1999) . Cell physiology, as described by the above variables, is the expression of a particular cellular state that can be quantified by a variety of methods probing the trancriptional, proteomic and metabolic state of a cell. Since all cellular processes originate at the transcription level, it can be argued that transcriptional profiling provides a broad, albeit incomplete, descriptor of the cellular physiological state. Consequently, gene transcription measurements by various types of microarrays (Schena et al., 1995; Lockhart et al., 1996) contain information that should be useful, in principle, in defining the physiological state of a cell, such as whether it is in a diseased or non-diseased state. However, although no one doubts the value of information residing in microarray expression data (collectively referred to as the expression phenotype) it is yet not clear how these data can be used in a comprehensive definition of the physiological state of a cell.
Gene expression data obtained at various cellular states may be used for discovery and classification. In discovery, the goal is to unveil distinct physiological states or disease subtypes, along with the genes that distinguish them, though the number and nature of these states is not usually known. Discovery is usually a difficult and uncertain task. Multivariate analysis tools such as principal component analysis (PCA, or as it is known in the microarray field, the singular value decomposition, SVD) are useful for visualizing the data structure in a reduced number of dimensions, and can play a valuable role in the data-driven or discovery aspect of microarray data analysis (Dillon and Goldstein, 1984; Wen et al., 1998; Alter et al., 2000; Holter et al., 2000) . Other tools include unsupervised clustering methods, such as hierarchical clustering, and self-organizing maps (SOMs) (Dillon and Goldstein, 1984; Eisen et al., 1998; Tamayo et al., 1999; Golub et al., 1999) . A second use of microarray data is for classification, where a priori knowledge of the various physiological states is used along with gene expression measurements in order to discriminate between the various physiological states and classify unknown samples in one of several possible groups or classes. Though usual class discovery tools, with modifications, can be applied to this task, in this aspect of the analysis fundamentally different questions are being asked that require a different set of tools. For example, non-linear classifiers, such as support vector machines (SVM; Furey et al., 2000) have been used to classify samples for diagnostic purposes. Although these provide good classification, they do so at the cost of interpretability. When applied to expression data, their complexity and non-linearity impede estimation of the influence that any one particular gene may have on the overall physiological state. In addition, these classifiers do not provide easily interpretable visualizations of the data. Microarray studies have now been conducted which consider anywhere from two classes (Tao et al., 1999) to multiple classes and subtypes (Golub et al., 1999; Alizadeh et al., 2000) within a single experiment. Therefore, a good classification method should be able to handle any number of input classes while still providing intuitive visualization and interpretability.
In view of these limitations, we are in need of a method that, (a) facilitates the visualization of the separation of samples among classes in the case where many classes exist, (b) explicitly connects individual genes to discriminating characteristics among classes and thus provides insights into underlying physiology in terms of these genes and their interactions, and (c) is robust in classification.
We propose the use of projections defined by Fisher discriminant analysis (FDA) to overcome the limitations inherent in the techniques described above in classifying (or mapping) cellular a priori known physiological states from gene expression measurements. FDA classifies samples based on the value of linear composites of genes. The sheer magnitude of the expression phenotype necessitates that either a small number of genes or composites of gene expression measurements be used in the definition of the physiological state. Concentrating on only a few genes implies that, despite its apparent complexity, cellular function is still determined by a small number of genes, a corollary that is not supported by the accumulating evidence of microarray data (Golub et al., 1999) . The use of composites of gene expression measurements in lieu of the expression measurements themselves, however, allows for consideration of all genes of interest by projecting the expression phenotype into a lower-dimensional space where the various physiological states can potentially be identified.
Projection of the samples in the lower-dimensional FDA space allows for separation of the samples according to their physiological state. Hence, the FDA space is analogous to a 'physiological space', where the samples are grouped according to their physiological phenotype, as reflected in the expression phenotype. Although the FDA methodology is used for classification, it yields biologically intuitive visualizations, and provides a direct link to biology through the interpretation of the genes.
METHODS
FDA is a classification method that operates by determining a set of orthonormal dimensions where the separation between the given classes is maximized. The dimensions generated by FDA are known as the discriminant functions (DFs), and they are linear combinations of the primary variables, or dimensions. In the case of microarray data, the number of dimensions in the original data space is the number of genes, g, whose expression was monitored. Each DF is uncorrelated with the others (since they are orthonormal), an aspect which increases the interpretability of the visualization. FDA is similar to PCA in as much as it reduces the number of significant dimensions in the data by generating linear combinations of the genes which are then used to project the samples. However, they differ in the objective function being maximized in the dimensionreduction process: while PCA attempts to capture the most amount of variation in the reduced dimensions, FDA attempts to maximize the separation between the pre-ordained sample classes in the reduced-dimensional space. For this reason, FDA is a better classification tool (Zhao and Maclean, 2000) .
Generation of discriminant axes/linear composites FDA defines a projection from the original to a reduced space that maximizes the ratio of the variance-betweengroups to the variance-within-groups. This is mathematically equivalent to maximizing the mean separation between the various groups or classes in the reduced dimensional space. If there are c classes in the data, the withingroup-variance W and the between-group-variance B are defined as:
where T is the total variation. X k and X are data matrices for samples in class k and the entire expression set, respectively. These matrices are organized such that X(i, j) is the expression of gene j in sample i.x k is the group mean (1 × g) for class k, whilex is the mean for all the data. It can be proved that the separation between pre-defined groups in a reduced-dimensional space is maximized when the space is defined by the eigenvectors of the matrix W −1 B (Dillon and Goldstein, 1984) . Mathematically, the eigenvalue decomposition of the matrix is given by:
The eigenvector matrix (L) defines the dimensions of the reduced space. Each column of L defines an axis or DF of the FDA space. The diagonal entries of the eigenvalue matrix ( ) represents the discriminant powers of each corresponding DF. The entries in L contain the discriminant weight for each gene. The discriminant weight determines the contribution of each gene in defining the DF. Finally, the projections of the individual samples onto each DF, or the discriminant score, is calculated by:
where y j is the discriminant score of the actual sample x on the jth DF. The individual discriminant scores for a sample on each DF can be combined in a vector y, whose dimensionality is the number of dimensions in the FDA space.
In order to get good classification from an eigenvalue decomposition, the variance-covariance structure must be similar in all the various classes. In cases where this assumption is not valid, we have found that the singular value decomposition of W −1 B produces better discriminant axes than the eigenvalue decomposition of W −1 B, and thus the axes more effectively capture the between group variance. For those cases, the singular value decomposition was applied to find the axes and to calculate the discriminant scores:
where U is the left singular vector, L is the matrix of discriminant axes, or the DFs, and is the singular values representing the discriminant powers along the corresponding axes. The calculation of the discriminant scores remains the same as before. It should be noted that here, singular value decomposition refers to the linear algebra technique of decomposing matrices, not the PCA technique as used by Alter et al. (2000) and (Holter et al., 2000) .
Dimensionality of the reduced discrimination space
In the formulation described above, the total number of DFs is equal to min (g, c) . Not all of these DFs will provide significant separation between the groups, and therefore, Bartlett's statistic, V j is used to assess the significance of each DF:
where λ j is the eigenvalue for the jth DF from the eigenvalue decomposition, and n, g and c are the number of samples, predictor variables (genes) and classes, respectively. The statistic V j approximately follows chi-square distribution with g + c − 2 j degrees of freedom. If the calculated value of V j is greater than a critical value from a χ 2 distribution with g + c − 2 j degrees of freedom, the DF (eigenvector j) is concluded to be significant. Also, the statistic V j can be used to determine whether the centroids of the discriminant scores for classes are statistically different. Since DFs are uncorrelated, the V j s can be added to give a total V that is used to assess the statistical significance of the entire reduced-dimensional space by comparing it to a χ 2 distribution with
, where r is the dimensionality of the reduced-dimension space). In practice, the application of this statistic V j to microarray data is limited, because the small number of samples results in negative V j values (g n in the above equation).
Development of a classifier using the group centroids
Once the initial set of samples has been projected into FDA space, and clear separation among the various classes is achieved, an FDA-based classifier for additional samples can be built on the r DFs. The process consists of first calculating the group centroid of the discriminant scores for each class. Then, the discriminant score of the new sample is determined, and its distance from each of the group centroids of discriminant scores is calculated. The sample is assigned to the class which has the nearest group centroid. Mathematically, a new sample x(1 × g) is assigned to class k if:
where L is the matrix of the r DFs obtained from the eigenvalue (or singular value) decomposition of W −1 B above,ȳ k is the centroid of discriminant scores in class k, andŷ j is the projection of the new sample into the jth DF (the jth axis).
Contributions of individual genes (predictor variables) to discrimination among classes
Once the FDA projection is obtained, the discriminant weights are examined to determine the importance of each gene in the resulting classification. This holds true for data 
where R is the correlation matrix of the data matrix and D 1/2 is the diagonal matrix of standard deviations for predictor variables (genes) (Dillon and Goldstein, 1984) . The above equation calculates the correlation of a gene to a DF. This calculation is not impeded by the intercorrelation among genes. Hence, if two strongly correlated genes are both important for defining a DF, they will have similar loadings. Although not used in the current study, sometimes interpretation of the significance of the predictor variables for classification can be improved through the rotation of the discriminant weights/loadings under adequate criteria such as varimax and promax (Johnson and Wichern, 1992) . The absolute value of the rotated discriminant weights/loadings will typically be closer to one or zero, more clearly identifying genes as important to discrimination or not, respectively.
Pre-selection of discriminating genes
When a large number of variables (genes) are employed, the risk of obtaining a poor FDA classification increases due to the increased likelihood of noisy variables. Therefore, in most cases of microarray data analysis, some form of gene selection methodology must be implemented prior to classification, to screen out noisy and nondiscriminating genes. In our analysis, we chose Wilks' lambda defined as the ratio of the determinant of the between-group variance matrix W to the determinant of the total variance matrix T for each gene to obtain an initial set of discriminatory genes (Dillon and Goldstein, 1984) . Wilks' lambda can be transformed into an Fdistribution, which allows the selection of discriminatory genes with an appropriate confidence level. This set of genes was further refined by retaining only those genes that yield low misclassification rates in a leave-one-outcross-validation procedure. In the construction of the FDA classifier, one sample from each class was removed from analysis, and the classifier built on the remaining samples using the given set of genes. The classifier was then used to predict the class of the withheld samples. This procedure was repeated for all the samples for the given set of genes and the final cumulative error was recorded. Then, the gene with the lowest value of Wilks' lambda was removed, and the cross-validation procedure repeated to obtain a new cumulative error. The set of genes that had a minimum cumulative error was chosen for use with FDA. The overall approach is described schematically in Figure 1 .
RESULTS
We applied FDA projections to four examples of gene expression phenotypes generated in our laboratory and also published in the literature, to illustrate the various applications of this technique, and its flexibility. Figure 2A shows the FDA application to gene expression data of 10 samples from five normal and five malignant oral epithelium tissues (Alevizos et al., 2001) . Wilks' lambda was used to identify 171 most discriminating genes from a total of 7070 genes with a stringent 99% confidence level. In addition, the misclassification rate from leave-one-out-cross-validation was used to select 35 genes out of the 171 genes for use with FDA (SAS/STAT User's Guide, 1989). Only one DF can be generated from the eigenvalue decomposition. However, the statistic V cannot determine the statistical significance of any DF, because the number of samples is so small that the resulting V value becomes negative. The projection of the scores using the 35 gene expressions separate the normal samples from the malignant samples in the one-dimensional discrimination space, characterizing oral epithelium malignancy. The discriminant loadings in Figure 2B show that two groups of genes distinguished by their signs in the loadings are identified and are differently regulated (anti-regulated) to produce the two different physiological states, normal and malignancy. One group of genes with the positive coefficients, down-regulated in cancer tissues, includes NmU, aldehyde dehydrogenase 9 and 10, Her3, etc., while the other group with negative coefficients, up-regulated in cancer tissues, includes ferritin, Urokinase plasminogen activator, Gro2 oncogene, among others (for detailed list of genes, see captions in Figure 2 ).
Two physiological classes
Multiple classes: correspondence in the patterns observed in the score and the discriminant loading plots As another example, this procedure was applied to the expression phenotypes measured in samples from patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (Golub et al., 1999) . Additionally, the ALL samples were further subdivided into Blineage ALL and T-lineage ALL (B-ALL and T-ALL, respectively). To reduce the number of genes considered, the Wilks' lambda measure was used again to uncover those genes that provide significant discrimination among the three classes by exceeding the critical value of the F distribution of Wilks' Lambda at 0.01 significance level. 1226 genes met this criterion of which 50 genes were selected for use in the FDA projection based on the misclassification rate obtained from leave-one-out cross validation (SAS/STAT User's Guide, 1989). The statistics showed that the three leukemia subtypes (groups) are separable by two DFs ( Figure 3A) , each of which is statistically significant (V 1 = 193.0641, V 2 = 124.9875, and V = 318.0516). Discriminant loadings are shown in Figure 3B . They closely follow the pattern in Figure 3A , and show how these 50 genes individually behave and interact to separate the three disease classes: (1) the genes are clustered into three groups, analogous to the clustering of the samples, (2) each gene has its specific contribution to a particular class except two genes between AML and T-ALL specific genes, and (3) all genes in each gene group have common expression patterns, which might be considered as co-regulation patterns. The specificity of a group of genes to a particular sample class implies that the expressions of the group of genes are highly elevated only in the sample class and down-regulated in the other classes.
Multiple classes: a framework for the analysis of the contributions of individual discriminant functions
In this example, cultures of the photosynthetic bacterium Synechocystis sp. PCC 6803 were cultivated through an initial period of 48 h of growth under light followed by 24 h of darkness. The cultures were subsequently subjected to two cycles of light and dark periods of 100 minites each and samples were collected during these periods for transcriptional analysis ( Figure 4B ). The expression levels of 88 genes associated with harvesting of light energy and central carbon metabolism were measured at 23 time points (29 total samples, including duplicates) using DNA microarrays (Gill et al., 2002) . Total signal to noise ratio of the microarray fluorescence was determined to be c.a. 4.0 indicating that background noise minimally interfered with the fluorescence of hybridized spots. The standard deviation of expression measurements, evaluated from microarray to microarray measurements, as well as from intra-microarray triplicate spots, was 45% suggesting that greater than 90% difference in fluorescence is significant at a 95% confidence level. The samples were divided into four classes, or phases. Phase I consisted of samples which had been exposed only to light, before being switched to the dark. Phase II samples were the ones collected after a 24 h period of darkness. Phase III samples were the ones taken every 10 min during the transient light cycle of the experiment, and Phase IV samples consisted of the ones taken every 10 min in the final transient dark phase of the experiment. Of the 88 total genes considered, 27 discriminatory genes were identified based on their Wilks' lambda measure with a stringent 99% confidence level. Figure 4A shows the projection of the expression phenotype of the 27 Synechocystis discriminatory genes to the FDAdefined discrimination space. The statistic V was used to determine that all three possible DFs are statistically significant (V 1 = 80.0597, V 2 = 62.4680, and V 3 = Fig. 3 . FDA projection of expression data obtained from patients with B-ALL, T-ALL, and AML. (A) Projection of the samples using 50 discriminatory genes allows FDA to clearly separate the three classes of leukemia expression phenotype in a two-dimensional discrimination space. The first DF distinguishes the T-ALL group from B-ALL and AML. The second DF separates B-ALL group from AML to complete the group separation. (B)The contributions of individual genes to the discrimination and their interactions are evident on plotting the discriminant loadings, where the genes are clustered into three groups, and show group-specific regulation patterns, except two genes between AMLspecific gene group and T-ALL specific gene group. Ten of the 14 AML specific genes observed above are common with the 25 AML genes identified by Golub et al. (1999) , two of the 25 T-ALL and two of the nine B-ALL genes above are common with the 25 ALL genes identified by Golub et al. (1999) . The identity of these genes is provided in Supplementary Materials. This photosynthetic bacterium was grown under conditions shown in (B) and the expression levels of 88 genes were measured by a DNA microarray at 29 time points spanning the entire course of the experiment. Of the 88 genes, 27 were identified as most discriminating of the four classes defined by the four different light conditions and their expression levels were projected to the FDA-defined space. It can be seen that the four phenotypic classes are clearly identified in the three-dimensional FDA projection space. (C) The first DF shows the largest discrimination power separating all the groups, discriminating clearly Phase III from the others. The second DF separates Phase IV from Phases I and II, while the third DF is necessary to separate Phase I from II.
22.4723) and the centroids of the scores are statistically different (V = 165). Thus, three DFs in the projection space effectively distinguish the four phenotypic classes of growth under the light and dark conditions shown in Figure 4B . The two-dimensional diagrams of the three DFs ( Figure 4C ) illustrate how the individual DFs discriminate the four classes. DF1 distinguishes group 2 from the other groups while DF2 separates groups 1 and 3. Hence, the second discriminant weights provide information on the identity of the genes supporting the differences in the cellular processes occurring under light and dark conditions.
Multiple classes: using an established 'physiological space' for the classification of unknown samples The compendium of gene expression data published by Rosetta Inpharmatics (Hughes et al., 2000) was also analyzed. In this study, gene expression profiles were reported for single gene deletion mutants of yeast as well as of wild-type yeast cells treated with various drugs. Here, we first classified related single-gene deletion mutants of yeast into four groups on the basis of the presumed function of the deleted gene and also by applying clustering algorithms. In identifying discriminatory genes, of the 1756 genes that met Wilks' lambda criterion, 200 genes were selected for the FDA projection based on the misclassification rate obtained from leave-one-out cross validation. By projecting the expression phenotype of the four groups of the related single gene deletion mutants onto the threedimensional space defined by FDA, four distinct physiological states were identified characteristic of the genetic disruptions in the mutants of each group: mitochondrial activity, cell wall synthesis, ergosterol synthesis, and protein synthesis ( Figure 5 ). As in the first example, the statistic V cannot determine whether the DFs are statistically significant, due to the small number of samples relatively to the genes considered. A classifier to discriminate the The proximity in FDA space of these projections to those of the expression phenotype of the deletion mutant groups helps characterize the action of the compound on cell physiology. Note that one compound experiment (Cal) which appears incorrectly classified is actually in the center of the three-dimensional diagram, and not clearly associated with any of the groups shown. The classification suggested by the proximity of the projected phenotypes to the deletion mutants groups agrees with classification provided by Hughes et al. (2000) .
four classes of deletion mutants was built using the gene expression measurements and used to project the drugtreated samples into the space defined by the deletion mutants. The projections of Figure 5 show how the action of a drug causes a nearly equivalent physiological state as a disruption through genetic deletion, based on the assignments of the expression measurements in drug treated tissues to four deletion mutant groups. This example also illustrates how generation of a physiological classification state using FDA can be used to analyze and categorize new samples, and thus systematically build on a previous body of knowledge.
DISCUSSION
This study illustrates the use of FDA in providing a classification of physiological states using microarray data. For the four cases considered, the FDA allowed for: (a) convenient visualization of sample classes and construction of a classifier in a reduced-dimensional space, (b) analysis of the contribution of individual genes to the discrimination patterns observed in the samples, and (c) good classification of the samples.
An FDA-based classifier, and the important predictor variables characterizing the discrimination can be used to achieve various goals in medical and biotechnological applications. The FDA classifier can correctly diagnose a disease subtype present in a sample and efficiently screen candidate drugs as shown in the last example ( Figure 5 ). The important genes identified through FDA can aid in defining the means to make a desired change in the physiological state that restores the expression phenotype to that of a normal tissue. In addition, the group specific genes shown in Figures 3B and 2B may potentially yield markers useful in disease diagnosis. In the biotechnological area, the important variables can be used to help control bioreactors to establish a desirable pattern of gene expression that corresponds to high productivity based on the classifier and the important variables.
FDA is an optimal classification procedure in the sense of producing the smallest misclassification error rates under the following assumptions: (1) multivariate normality of the g predictor variables, and (2) equal covariance matrices in each of the c groups. For data meeting these two assumptions, FDA produces the same classification rule, and thus the same error rate as maximum likelihood classification. Although multivariate normality is not an essential factor in the FDA-based classification, the equality of covariance matrices is a key factor strongly affecting the classification performance. The equality of covariance matrices is highly influenced by the number of predictor variables. Thus, in most gene expression measurements where the covariance matrices are different to a moderate extent, the number of the predictor variables (genes) should be determined carefully to minimize the effect of inequality of the covariance matrix on classification performance.
Accordingly, an initial set of discriminatory genes should be obtained based on Wilks' lambda and then a subset of these screened genes should be further selected based on the misclassification rate obtained from crossvalidations. In general, too small a number of genes do not provide the FDA classifier with complete discriminatory information, while too many genes contaminate the classifier with non-discriminatory information from the genes with overlapping expressions across the classes. In our analysis, the initially screened genes determined by considering Wilks' lambda were an upper bound on the set of discriminatory genes. This set contained many genes with small discriminatory characteristics whose F values (transformed from Wilks' lambda) are only slightly larger than the critical value. Such genes with small discriminatory characteristics were eliminated based on the cross-validation misclassification rate, before the application of FDA.
Although other classification methods, such as SVM, have been applied to high-throughput expression analysis in the two-class case, they lack the simplicity, visualization, and interpretability characteristics of FDA. Application of other methods may yield different classifications, and may point to a different set of genes as important in the discrimination. In general, we would suggest that conclusions about sample diagnosis and importance of individual genes in defining cell physiology be based on a consensus from a multiplicity of methods. In this sense, FDA belongs in the portfolio of techniques to be used for this purpose.
It should be noted that the FDA method requires that a priori classification of samples be provided. Although this was rather straightforward for the cases presented, we note that, in general, this is not a trivial matter. For example, samples may be classified as malignant without any note as to the type of specific cancer involved, or, in production systems, a state of low productivity may reflect more than one-expression phenotypes. Although such heterogeneous samples will generally produce less well-defined states in their FDA projections, one can take further steps to identify possible subdivisions within a particular physiological class using MANOVA in the discrimination space (Johnson and Wichern, 1992) .
Although the expression phenotype is an ample measure of the cellular state, it is by no means a complete one. As the techniques for probing the proteomic and metabolic state of the cell improve, a more comprehensive picture of cellular state will emerge. This data can nevertheless be handled by the same projection approach described herein. In this way, the use of projections to describe physiological state is as flexible as the data available and will find further applications as the type and volume of data accumulate in the future.
